Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03263130 · ClinicalTrials.gov registry record
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
A clinical trial of Emphysema and COPD, Emphysema, Asthma COPD Overlap, sponsored by Gelb, Arthur F., M.D..
- Recruiting
- Registry status
- 60
- Enrollment target
- 2
- Study locations
NCT03263130 is a study of Emphysema and COPD, Emphysema, Asthma COPD Overlap that is actively recruiting participants, run by Gelb, Arthur F., M.D.. The registered enrollment target is 60 participants, below the 3,801-participant average among 25 other Emphysema trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03263130, a study of Emphysema and COPD, Emphysema, Asthma COPD Overlap, is actively recruiting participants, sponsored by Gelb, Arthur F., M.D..
- RECRUITING
- Registry status
- 60 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).
Conditions Studied
Interventions
- OTHER As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
Study Locations (2)
California
- Arthur F Gelb MD - Lakewood
- Arthur F Gelb MD - Lakewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-01-01 |
| Est. Completion | 2027-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03263130
The ClinicalTrials.gov registry entry for NCT03263130 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,801-participant average among 25 other Emphysema trials with a reported enrollment target (98% lower). The listed sponsor is Gelb, Arthur F., M.D., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Emphysema appearing as the primary indexed condition, and to 1 intervention - of which As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap is the first listed.
NCT03263130 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03263130 about?
NCT03263130 is a clinical study titled "Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap". The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (\>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatm...
What is the current status of trial NCT03263130?
This trial is currently recruiting. The enrollment target is 60 participants. The study started on 2017-01-01. Estimated completion is 2027-12-01.
What conditions does trial NCT03263130 study?
This clinical trial studies the following conditions: Emphysema, COPD, Emphysema, Asthma COPD Overlap.
What interventions are being tested in trial NCT03263130?
The interventions under investigation include: As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap (OTHER).
Who is sponsoring clinical trial NCT03263130?
This trial is sponsored by Gelb, Arthur F., M.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03263130 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Emphysema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
COPD Patient-Powered Research Network
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
RECRUITING · NA
-
Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD
RECRUITING · NA
-
STRIVE Post-Market Registry Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.